Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

New Agreement

20 Jan 2005 07:01

Angle PLC20 January 2005 For Immediate Release 20 January 2005 ANGLE plc ANGLE signs Agreement with Ben Franklin Technology Partners to advance the growth of Technology Companies in Pennsylvania ANGLE plc, a leading international venture management and consulting companyfocusing on technology commercialisation today announced that it has signed aMemorandum of Understanding (MOU) with Ben Franklin Technology Partners ofSoutheastern Pennsylvania (BFTP/SEP), an internationally recognised economicdevelopment organisation, to advance the growth of technology-based companies inthe Greater Philadelphia region. Under the terms of the MOU, it is contemplated that ANGLE will commit no lessthan $5 million over five years for funding new technology spin-outs that meetits Progeny(R) requirements. This funding will be matched by BFTP/SEP - thusdoubling the leverage on ANGLE funds for creating ventures and similarlyleveraging BFTP/SEP's economic development funds. The Greater Philadelphia region is home to many of the world's most renownedacademic institutions including the University of Pennsylvania - one of theleading research universities in the United States. Collectively, the region'sacademic institutions attract more than $1 billion of research funding perannum, generating more than 200 patent applications per year. The region iswell recognised as a global leader in the bio-pharma and medical research arena. As part of the MOU, ANGLE will serve as BFTP/SEP's preferred commercialisationpartner for technologies from universities, colleges and related institutions inthe region, and become a corporate member of the Nanotechnology Institute, aninternationally recognised alliance of business, academia and government that isfacilitating the research and development and commercialisation of bio/nanoadvances. Commenting on the joint venture, Dr. Gary Evans, CEO of ANGLE's U.S. businessoperations said, "Our MOU and partnership with BFTP/SEP provides a uniqueopportunity both to extend our base of operation in the U.S. Mid-Atlantic regionand to complement an already robust technology commercialisation community. Inaddition to its formidable research capabilities, and its pre-eminentpharmaceutical industry, the region is highly regarded for developing newcutting edge research-to-commercialisation models around nanotechnology and bio/nanotechnology." "The ANGLE MOU is indicative of the synergy that occurs when distinct entitiesshare a common goal. It addresses critical management and capital needs at theearliest points in the commercialisation of new discoveries - just pasttranslational research to pre-seed, including pre-proof of concept,pre-prototype, pre-science/management team, pre-company formation. Liketechnology, this cross-Atlantic partnership has the potential to have asignificant global impact," said RoseAnn B. Rosenthal, president and CEO of BFTP/SEP. Andrew Newland, Chief Executive of ANGLE plc said, "This is a major developmentof our Ventures business in the U.S. It demonstrates the success of ourbusiness model and the leverage we generate between our Consulting and Venturesbusinesses. Our relationship with BFTP/SEP has developed from successfulconsulting work in Pennsylvania for Ben Franklin and others, including thedevelopment of the strategy for nanotechnology in the Commonwealth ofPennsylvania. We look forward to developing world-class ventures as a result ofthis expanded partnership." Notes to Editors: Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE plc floated on the Alternative Investment Market of the London StockExchange on 17 March 2004. About Ben Franklin Technology Partners of Southeastern Pennsylvania Since 1982, Ben Franklin Technology Partners of Southeastern Pennsylvania (BFTP/SEP) has helped grow the region through science, technology andentrepreneurship. BFTP/SEP provides entrepreneurs and established businesses thecapital, talent, and expertise they need to compete in the global marketplace.Like its namesake, Ben Franklin invests in, builds upon and delivers solutionsthat grow communities and create wealth by supporting today's technologicalideas and tomorrow's scientific discovery. For further information: ANGLE plc 01483 295830Andrew Newland, Chief ExecutiveDawson Buck, Deputy Chief Executive Buchanan Communications 020 7466 5000Richard Darby, Suzanne Brocks This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
29th Oct 20257:00 amRNS-RCHANGE OF NAME
16th Oct 20257:00 amRNSAppointments: Interim CEO and senior board advisor
8th Oct 20257:00 amRNSStrategy Update
29th Sep 20257:00 amRNS-RPresentation of Data on Glioblastoma
12th Sep 20257:00 amRNSBoard Changes
9th Sep 20257:01 amRNSInterim Results
9th Sep 20257:00 amRNSChange of Adviser
5th Sep 20252:58 pmRNSNotice of Results
20th Aug 20257:00 amRNSANGLE announces collaboration with Myriad Genetics
8th Jul 20257:00 amRNS-RPARSORTIX ENABLES STUDY OF CANCER PROGRESSION
30th Jun 20255:50 pmRNSResult of 2025 Annual General Meeting
17th Jun 20257:00 amRNS-REACR 2025: Innovation in AR expression profiling
17th Jun 20257:00 amRNS-REACR 2025: Data demonstrating DNA dual analysis
10th Jun 20257:00 amRNS-RNovel discoveries into the biology of cancer
9th Jun 20257:00 amRNSPOSTING OF ANNUAL REPORT AND NOTICE OF AGM
6th Jun 20257:00 amRNSBoard Changes
28th May 20257:00 amRNSPreliminary Results
23rd May 20257:00 amRNSNotice of Results
28th Apr 20257:00 amRNS-RRESULTS SUPPORTING ANGLE’S HER2 ASSAY PROGRAMME
21st Mar 20257:00 amRNSIssue of LTIP Options and Share Options
21st Mar 20257:00 amRNSResults of Eisai Phase 2 pilot study
6th Feb 20257:00 amRNS-RNovel findings using Parsortix
29th Jan 20257:00 amRNSAnalysis of CTC-DNA and ctDNA using Illumina assay
24th Jan 202510:05 amRNS-RParsortix used in research paper from ETH Zurich
23rd Jan 20257:00 amRNSTrading Update
26th Sep 20247:00 amRNSHalf-year Report
23rd Sep 20247:00 amRNSExclusive agreement for DNA NGS panel
17th Sep 20247:00 amRNSNotice of Interim Results and Webcast
18th Jul 202410:08 amRNSStandard form for notification of major holdings
12th Jul 20243:38 pmRNSStandard form for notification of major holdings
11th Jul 20243:07 pmRNSResult of 2024 Annual General Meeting
21st Jun 20247:00 amRNSResult of open offer
18th Jun 20242:41 pmRNSPosting of 2023 Annual Report & Notice of the AGM
11th Jun 20247:00 amRNSParsortix and assays being showcased at EACR 2024
6th Jun 20244:37 pmRNSPublication of Circular
5th Jun 20244:04 pmRNSResults of placing and subscription
5th Jun 20247:00 amRNSProposed Placing, Subscription and Open Offer
5th Jun 20247:00 amRNSPreliminary Results
16th May 20247:00 amRNSStudy of ovarian cancer CTCs using Parsortix
3rd May 20247:00 amRNSNew commercial agreement with large pharma
24th Apr 20247:00 amRNSNew commercial agreement with AstraZeneca
22nd Apr 20247:00 amRNSUS and EU patents for innovative CellKeep™ slide
8th Apr 20247:00 amRNSParsortix HER2 assay showcased at AACR 2024
22nd Mar 20247:00 amRNSParsortix at European breast cancer conference
22nd Jan 20247:00 amRNSPotential utility in precision oncology
10th Jan 202412:57 pmRNSStandard form for notification of major holdings
4th Jan 20247:00 amRNSBreakthrough clinical results
2nd Jan 20247:00 amRNSContract announcement with Eisai Inc.
11th Dec 20237:00 amRNSBroker Announcement
11th Dec 20237:00 amRNSParsortix unlocks opportunities for drug discovery

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.